SP 141 is primarily investigated for its potential in cancer therapy, specifically as a targeted treatment for triple-negative breast cancer (TNBC). It functions by inhibiting the heat shock protein 70 (Hsp70), which plays a key role in cancer cell survival by preventing apoptosis and supporting protein stability under stress. By disrupting Hsp70 activity, SP 141 promotes the degradation of oncoproteins and induces cancer cell death.

This compound has shown efficacy in preclinical studies by reducing tumor growth and metastasis, particularly in models resistant to conventional chemotherapy. Its ability to selectively target cancer cells with minimal effect on normal cells makes it a promising candidate for further development in oncology. Research is ongoing to evaluate its potential in combination therapies and its effectiveness against other Hsp70-dependent cancers.